+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Inactivation Market - Global Forecast 2026-2032- Product Image
Viral Inactivation Market - Global Forecast 2026-2032- Product Image
Sale

Viral Inactivation Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4986084
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Viral Inactivation Market is projected to reach USD 863.85 Million in 2026. It is expected to continue growing at a CAGR of 9.50%, reaching USD 1.48 Billion by 2032.

Viral inactivation is a core bioprocessing control used to reduce the risk of adventitious and endogenous viruses in biologics, vaccines, plasma-derived therapies, cell and gene therapies, and recombinant proteins. The discipline is anchored in internationally recognized expectations, including ICH Q5A(R2), FDA biologics guidance, EMA quality requirements, WHO recommendations, and pharmacopeial standards that emphasize orthogonal viral safety controls across raw materials, manufacturing, and release.

For biopharmaceutical manufacturers, the viral inactivation market is shaped by rising biologics approvals, increasing demand for monoclonal antibodies and complex proteins, and sustained regulatory scrutiny of viral clearance validation. Low-pH hold, solvent-detergent treatment, pasteurization, and complementary filtration steps remain central to validated manufacturing strategies, while single-use systems and intensified processing are changing how viral inactivation is designed, monitored, and documented.

Transformative Shifts in Viral Inactivation

The viral inactivation landscape is shifting from conventional batch-centric processing toward more integrated, platform-based, and risk-based viral safety strategies. ICH Q5A(R2), adopted in 2023, reinforces lifecycle management, prior knowledge, and platform validation, which is particularly important for manufacturers producing multiple biologics through comparable unit operations.

Transformative change is also coming from continuous manufacturing, closed processing, and single-use technologies. These approaches can reduce contamination risk and improve operational flexibility, but they require tighter control of critical process parameters such as pH, temperature, exposure time, mixing, and hold conditions. As biologics pipelines expand into bispecific antibodies, viral vectors, recombinant vaccines, and next-generation proteins, viral inactivation strategies must be tailored to product sensitivity while still meeting robust viral clearance expectations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing viral inactivation by improving process understanding, deviation detection, and predictive modeling. AI-enabled analytics can help correlate process parameters with viral clearance outcomes, identify process drift earlier, and support quality-by-design programs when trained on validated manufacturing and laboratory datasets.

The most practical near-term impact is in digital quality management, electronic batch record review, process monitoring, and experimental design for viral clearance studies. However, AI does not replace validated viral clearance testing. Regulators still expect scientifically justified models, representative scale-down studies, traceable data integrity, and documented human oversight before AI-derived insights can support GMP decisions.

Key Regional Insights for Viral Inactivation

North America remains a leading region for viral inactivation adoption due to the United States’ large biologics manufacturing base, strong FDA oversight, extensive contract development and manufacturing infrastructure, and advanced capabilities in monoclonal antibodies, vaccines, and advanced therapies. Canada adds clinical manufacturing, vaccine development, and academic translational capacity, while Mexico is increasingly relevant for regional supply chain resilience, nearshoring of life sciences operations, and expanding pharmaceutical manufacturing integration.

Europe is defined by EMA-aligned quality expectations, mature GMP inspection systems, strong biologics clusters in Germany, France, Italy, Spain, and the United Kingdom, and advanced plasma fractionation and vaccine capabilities. Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, Singapore, and Australia invest in biologics, biosimilars, vaccines, clinical research, and contract manufacturing, supported by regulatory modernization and growing domestic healthcare demand. Latin America, led by Brazil and Mexico, is building local biologics and vaccine capacity to improve access and reduce import dependence, while the Middle East is prioritizing vaccine security, plasma self-sufficiency, and technology transfer through national health strategies. Africa is strengthening public health manufacturing infrastructure, regional vaccine initiatives, and biologics readiness, with viral inactivation becoming increasingly important for local production quality and global regulatory alignment.

Key Group Insights Across Global Alliances

ASEAN markets are strengthening regional biologics and vaccine capabilities through investments in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, making standardized viral safety practices increasingly important for regional manufacturing, technology transfer, and regulatory reliance models. The GCC is advancing biomanufacturing, plasma programs, vaccine readiness, and localized pharmaceutical production as part of national health security, economic diversification, and pandemic preparedness strategies.

The European Union benefits from harmonized regulatory frameworks, mature quality systems, cross-border clinical research, and strong biologics manufacturing networks, making it a central reference point for viral clearance expectations. BRICS countries are central to biosimilars, vaccine production, local biologics scale-up, and cost-efficient manufacturing capacity, with China, India, Brazil, Russia, and South Africa each emphasizing health sovereignty and domestic supply. G7 countries continue to influence viral inactivation standards through regulatory science, GMP inspection practices, advanced manufacturing investments, and public health preparedness. NATO member states indirectly shape demand through biosecurity priorities, pandemic preparedness, resilient medical supply chains, coordinated health security planning, and investment in critical healthcare infrastructure.

Key Country Insights for Viral Inactivation

The United States leads viral inactivation demand through biologics innovation, FDA-regulated manufacturing, extensive clinical and commercial production capacity, and deep expertise in monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies. Canada supports vaccine, cell therapy, biologics research, and clinical manufacturing development, while Mexico is gaining relevance as a North American life sciences manufacturing partner. Brazil remains Latin America’s key biologics and vaccine production hub, supported by public health manufacturing priorities, biosimilar adoption, and technology transfer programs.

In Europe, the United Kingdom contributes strong life sciences research, clinical development, and advanced therapy capabilities, while Germany combines engineering depth, biologics production, and rigorous quality systems. France has established vaccine, plasma-derived therapy, and biomanufacturing expertise; Italy supports pharmaceutical manufacturing, fill-finish, and biologics production; and Spain is strengthening biologics research, vaccine capacity, and contract manufacturing. Russia maintains domestic vaccine and biologics capabilities focused on supply security and national production. In Asia-Pacific, China and India drive biosimilar and vaccine scale-up through large manufacturing ecosystems and expanding regulatory capability, Japan emphasizes high-quality biologics, regulatory rigor, and process reliability, South Korea is a global leader in contract biomanufacturing and biosimilars, and Australia supports clinical trials, translational research, vaccine programs, and advanced therapy development.

Actionable Recommendations for Viral Inactivation Leaders

Industry leaders should align viral inactivation strategy with product modality, regulatory expectations, and lifecycle management from early development through commercial manufacturing. Building platform viral clearance packages, maintaining qualified scale-down models, and documenting prior knowledge can accelerate development while preserving compliance with ICH Q5A(R2), FDA, EMA, WHO, and pharmacopeial expectations.

Manufacturers should also invest in digital batch records, advanced analytics, single-use compatibility assessments, closed processing controls, and supplier qualification for critical raw materials. Cross-functional collaboration among process development, quality assurance, regulatory affairs, manufacturing science, and supply chain teams is essential to ensure that viral inactivation controls remain scientifically justified, inspection-ready, scalable, and resilient across global production networks.

Research Methodology

This executive summary is based on secondary research across regulatory guidance, pharmacopeial references, peer-reviewed literature, public regulatory documents, GMP inspection trends, and established bioprocessing industry sources. Key reference frameworks include ICH Q5A(R2), FDA and EMA biologics quality expectations, WHO guidance, and recognized viral clearance validation practices for biologics, vaccines, plasma-derived products, and recombinant therapies.

The research approach evaluates market dynamics by product modality, technology type, end user, geography, regulatory environment, and manufacturing model. Insights are validated through triangulation of public datasets, scientific consensus, regulatory documentation, and observed industry adoption patterns, with emphasis on evidence-backed interpretation rather than speculative market estimation, market sizing, market share, or forecasting.

Conclusion

Viral inactivation remains a foundational pillar of biologics safety and a strategic differentiator for manufacturers operating in regulated markets. As biologics portfolios diversify and global production networks expand, companies must combine proven viral clearance methods with modern process analytics, robust documentation, and harmonized quality systems.

The next phase of industry development will favor organizations that can validate viral inactivation efficiently, adapt to emerging modalities, and integrate digital tools without compromising regulatory confidence. Organizations that embed viral safety into process design, supply chain governance, technology transfer, and lifecycle management will be best positioned for resilient, compliant, and quality-driven growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Viral Inactivation Market, by Product
7.1. Introduction
7.2. Consumables
7.2.1. Chemical Kits
7.2.2. Disinfectant Solutions
7.2.3. Uv Lamps
7.3. Equipment
7.3.1. Filtration Equipment
7.3.2. Irradiation Equipment
7.3.3. Sterilization Equipment
8. Viral Inactivation Market, by Method
8.1. Introduction
8.2. Chemical Treatment
8.2.1. Chlorine Dioxide
8.2.2. Ethylene Oxide
8.2.3. Hydrogen Peroxide
8.3. Heat Treatment
8.3.1. Dry Heat
8.3.2. Moist Heat
8.4. Physical Treatment
8.4.1. Electron Beam
8.4.2. Gamma Radiation
8.4.3. Ultraviolet
8.4.3.1. Low Pressure Mercury
8.4.3.2. Pulsed Xenon
9. Viral Inactivation Market, by Application
9.1. Introduction
9.2. Air Purification
9.2.1. Hvac Systems
9.2.2. Portable Purifiers
9.3. Food Processing
9.3.1. Beverage Processing
9.3.2. Dairy Processing
9.3.3. Meat Processing
9.4. Pharmaceutical Manufacturing
9.4.1. API Production
9.4.2. Biologics Production
9.4.3. Vaccine Production
9.5. Water Treatment
9.5.1. Drinking Water Treatment
9.5.2. Wastewater Treatment
10. Viral Inactivation Market, by End User
10.1. Introduction
10.2. Biotechnology Firms
10.2.1. Diagnostic Developers
10.2.2. Therapeutics Developers
10.3. Food And Beverage Processors
10.3.1. Beverage Plants
10.3.2. Dairy Plants
10.3.3. Meat Plants
10.4. Healthcare Facilities
10.4.1. Clinics
10.4.2. Hospitals
10.5. Laboratories
10.5.1. Clinical Laboratories
10.5.2. Research Laboratories
11. Viral Inactivation Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Viral Inactivation Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Viral Inactivation Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Asahi Kasei Medical
15.2. Charles River Laboratories International, Inc.
15.3. Clean Cells Inc.
15.4. Danaher Corporation
15.5. Eurofins Scientific SE
15.6. Kedrion
15.7. Lonza Group AG
15.8. Merck KGaA
15.9. METTLER TOLEDO
15.10. Pall Corporation
15.11. Parker Hannifin Corporation
15.12. Rad Source Technologies, Inc.
15.13. Sartorius AG
15.14. Texcell SA
15.15. Thermo Fisher Scientific Inc.
15.16. Vironova AB
15.17. WuXi Biologics
List of Figures
FIGURE 1. GLOBAL VIRAL INACTIVATION MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VIRAL INACTIVATION MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VIRAL INACTIVATION MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VIRAL INACTIVATION MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VIRAL INACTIVATION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL VIRAL INACTIVATION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL VIRAL INACTIVATION MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CHEMICAL KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CHEMICAL KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CHEMICAL KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL DISINFECTANT SOLUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL DISINFECTANT SOLUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL DISINFECTANT SOLUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL UV LAMPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL UV LAMPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL UV LAMPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL EQUIPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL EQUIPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL EQUIPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL FILTRATION EQUIPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL FILTRATION EQUIPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL FILTRATION EQUIPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL IRRADIATION EQUIPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL IRRADIATION EQUIPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL IRRADIATION EQUIPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL STERILIZATION EQUIPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL STERILIZATION EQUIPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL STERILIZATION EQUIPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CHEMICAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CHEMICAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CHEMICAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CHLORINE DIOXIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CHLORINE DIOXIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CHLORINE DIOXIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ETHYLENE OXIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ETHYLENE OXIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ETHYLENE OXIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL HYDROGEN PEROXIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL HYDROGEN PEROXIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL HYDROGEN PEROXIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HEAT TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HEAT TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HEAT TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL DRY HEAT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DRY HEAT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DRY HEAT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MOIST HEAT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MOIST HEAT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL MOIST HEAT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PHYSICAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PHYSICAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PHYSICAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ELECTRON BEAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ELECTRON BEAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ELECTRON BEAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL GAMMA RADIATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GAMMA RADIATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GAMMA RADIATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ULTRAVIOLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ULTRAVIOLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ULTRAVIOLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LOW PRESSURE MERCURY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LOW PRESSURE MERCURY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LOW PRESSURE MERCURY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PULSED XENON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PULSED XENON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PULSED XENON MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL AIR PURIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL AIR PURIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL AIR PURIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HVAC SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HVAC SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HVAC SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PORTABLE PURIFIERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PORTABLE PURIFIERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PORTABLE PURIFIERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL FOOD PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL FOOD PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL FOOD PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL BEVERAGE PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BEVERAGE PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BEVERAGE PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL DAIRY PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL DAIRY PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL DAIRY PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MEAT PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MEAT PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL MEAT PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL API PRODUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL API PRODUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL API PRODUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BIOLOGICS PRODUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL BIOLOGICS PRODUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL BIOLOGICS PRODUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL VACCINE PRODUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL VACCINE PRODUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL VACCINE PRODUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL WATER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL WATER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL WATER TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL DRINKING WATER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL DRINKING WATER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL DRINKING WATER TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL WASTEWATER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL WASTEWATER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL WASTEWATER TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL BIOTECHNOLOGY FIRMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL BIOTECHNOLOGY FIRMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL BIOTECHNOLOGY FIRMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL DIAGNOSTIC DEVELOPERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL DIAGNOSTIC DEVELOPERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL DIAGNOSTIC DEVELOPERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL THERAPEUTICS DEVELOPERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL THERAPEUTICS DEVELOPERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL THERAPEUTICS DEVELOPERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL FOOD AND BEVERAGE PROCESSORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL FOOD AND BEVERAGE PROCESSORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL FOOD AND BEVERAGE PROCESSORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL BEVERAGE PLANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL BEVERAGE PLANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL BEVERAGE PLANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL DAIRY PLANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL DAIRY PLANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL DAIRY PLANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL MEAT PLANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL MEAT PLANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL MEAT PLANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL HEALTHCARE FACILITIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL HEALTHCARE FACILITIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL HEALTHCARE FACILITIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL CLINICAL LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL CLINICAL LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL CLINICAL LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 179. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 190. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 192. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 193. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 194. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 195. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 196. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 197. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 209. EUROPE VIRAL INACTIVATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 210. EUROPE VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 211. EUROPE VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 212. EUROPE VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 213. EUROPE VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 214. EUROPE VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 215. EUROPE VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 216. EUROPE VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 217. EUROPE VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 218. EUROPE VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 219. EUROPE VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 220. EUROPE VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 221. EUROPE VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 222. EUROPE VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 223. EUROPE VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. EUROPE VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 225. EUROPE VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 226. EUROPE VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 227. EUROPE VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 228. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 229. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 230. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 231. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 234. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 235. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 236. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 237. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 240. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 247. AFRICA VIRAL INACTIVATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 248. AFRICA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 249. AFRICA VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 250. AFRICA VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 251. AFRICA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 252. AFRICA VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 253. AFRICA VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 254. AFRICA VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 255. AFRICA VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 256. AFRICA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 257. AFRICA VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 258. AFRICA VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 259. AFRICA VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 260. AFRICA VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 261. AFRICA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. AFRICA VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 263. AFRICA VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 264. AFRICA VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 265. AFRICA VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 266. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 267. ASEAN VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 268. ASEAN VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 269. ASEAN VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 270. ASEAN VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 271. ASEAN VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 272. ASEAN VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 273. ASEAN VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 274. ASEAN VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 275. ASEAN VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 276. ASEAN VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. ASEAN VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 278. ASEAN VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 279. ASEAN VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 280. ASEAN VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 281. ASEAN VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. ASEAN VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 283. ASEAN VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 284. ASEAN VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 285. ASEAN VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 286. GCC VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 287. GCC VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 288. GCC VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 289. GCC VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 290. GCC VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 291. GCC VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 292. GCC VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 293. GCC VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 294. GCC VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 295. GCC VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 296. GCC VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 297. GCC VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 298. GCC VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 299. GCC VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 300. GCC VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 301. GCC VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 302. GCC VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 303. GCC VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 304. GCC VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 324. BRICS VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 325. BRICS VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 326. BRICS VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 327. BRICS VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 328. BRICS VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 329. BRICS VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 330. BRICS VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 331. BRICS VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 332. BRICS VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 333. BRICS VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 334. BRICS VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 335. BRICS VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 336. BRICS VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 337. BRICS VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 338. BRICS VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. BRICS VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 340. BRICS VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 341. BRICS VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 342. BRICS VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 343. G7 VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 344. G7 VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 345. G7 VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 346. G7 VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2017-2032 (USD MILLION)
TABLE 347. G7 VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2017-2032 (USD MILLION)
TABLE 348. G7 VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 349. G7 VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2017-2032 (USD MILLION)
TABLE 350. G7 VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 351. G7 VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2017-2032 (USD MILLION)
TABLE 352. G7 VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 353. G7 VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2017-2032 (USD MILLION)
TABLE 354. G7 VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2017-2032 (USD MILLION)
TABLE 355. G7 VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2017-2032 (USD MILLION)
TABLE 356. G7 VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2017-2032 (USD MILLION)
TABLE 357. G7 VIRAL INACTIVATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 358. G7 VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2017-2032 (USD MILLION)
TABLE 359. G7 VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2017-2032 (USD MILLION)
TABLE 360. G7 VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2017-2032 (USD MILLION)
TABLE 361. G7 VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2017-2032 (USD MILLION)
TABLE 362. NATO VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 363. NATO VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 364. NATO VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION

Companies Mentioned

  • Asahi Kasei Medical
  • Charles River Laboratories International, Inc.
  • Clean Cells Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • Kedrion
  • Lonza Group AG
  • Merck KGaA
  • METTLER TOLEDO
  • Pall Corporation
  • Parker Hannifin Corporation
  • Rad Source Technologies, Inc.
  • Sartorius AG
  • Texcell SA
  • Thermo Fisher Scientific Inc.
  • Vironova AB
  • WuXi Biologics

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 863.85 Million
Forecasted Market Value ( USD ) by 2032 $ 1480 Million
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Medical Device Viral Inactivation Testing Market - Global Forecast 2026-2032 - Product Image

Medical Device Viral Inactivation Testing Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Viral Inactivation - Global Strategic Business Report - Product Image

Viral Inactivation - Global Strategic Business Report

  • Report
  • 234 Pages
  • Global
From
Viral Inactivation Market Report by Product, Application, End Use, and Region 2026-2034 - Product Image

Viral Inactivation Market Report by Product, Application, End Use, and Region 2026-2034

  • Report
  • 141 Pages
  • Global
From
Viral Inactivation Market Report 2026 - Product Image

Viral Inactivation Market Report 2026

  • Report
  • 250 Pages
  • Global
From
2025 Global Forecast for Viral Inactivation Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Viral Inactivation Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the Viral Inactivation Market

The Viral Inactivation market is a subset of the biotechnology industry that focuses on the development of technologies and processes to inactivate viruses. This is done through a variety of methods, such as chemical treatments, physical treatments, and irradiation. These treatments are used to reduce the risk of contamination and to ensure the safety of products, such as pharmaceuticals, biologics, and medical devices. Viral inactivation is also used in the production of vaccines and other biologics. Viral inactivation is an important part of the biotechnology industry, as it helps to ensure the safety of products and reduce the risk of contamination. It is also used to improve the efficacy of products, such as vaccines. Some companies in the Viral Inactivation market include Merck, Sartorius, Lonza, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.